Invesco
HRTX icon

Invesco’s Heron Therapeutics HRTX Stock Holding History

Invesco’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Buy
326,512
+18,651
+6% +$21.6K ﹤0.01% 3395
2025
Q4 		$400K Buy
307,861
+76,466
+33% +$94.4K ﹤0.01% 3283
2025
Q3 		$292K Buy
231,395
+58,314
+34% +$92.5K ﹤0.01% 3428
2025
Q2 		$358K Buy
173,081
+53,419
+45% +$109K ﹤0.01% 3300
2025
Q1 		$263K Buy
119,662
+48,263
+68% +$93.7K ﹤0.01% 3405
2024
Q4 		$109K Buy
71,399
+19,738
+38% +$32K ﹤0.01% 3614
2024
Q3 		$103K Buy
51,661
+10,336
+25% +$24.7K ﹤0.01% 3618
2024
Q2 		$145K Sell
41,325
-5,823
-12% -$17.9K ﹤0.01% 3702
2024
Q1 		$131K Sell
47,148
-10,164
-18% -$25.5K ﹤0.01% 3719
2023
Q4 		$97.4K Sell
57,312
-1,383
-2% -$1.52K ﹤0.01% 3691
2023
Q3 		$60.5K Sell
58,695
-8,999
-13% -$12.8K ﹤0.01% 3783
2023
Q2 		$78.5K Buy
67,694
+13,622
+25% +$24.3K ﹤0.01% 3765
2023
Q1 		$81.6K Sell
54,072
-33,706
-38% -$84.4K ﹤0.01% 3717
2022
Q4 		$219K Buy
87,778
+4,124
+5% +$13.3K ﹤0.01% 3648
2022
Q3 		$354K Buy
83,654
+3,214
+4% +$12.6K ﹤0.01% 3437
2022
Q2 		$225K Buy
80,440
+8,507
+12% +$34.2K ﹤0.01% 3689
2022
Q1 		$412K Buy
71,933
+9,371
+15% +$68.6K ﹤0.01% 3488
2021
Q4 		$571K Sell
62,562
-2,195
-3% -$22.4K ﹤0.01% 3335
2021
Q3 		$692K Sell
64,757
-1,649,533
-96% -$20.1M ﹤0.01% 3275
2021
Q2 		$26.6M Sell
1,714,290
-3,347
-0.2% -$53.2K 0.01% 1426
2021
Q1 		$27.8M Sell
1,717,637
-6,227
-0.4% -$111K 0.01% 1347
2020
Q4 		$36.5M Sell
1,723,864
-13,997
-0.8% -$243K 0.01% 1138
2020
Q3 		$25.8M Sell
1,737,861
-42,777
-2% -$667K 0.01% 1182
2020
Q2 		$26.2M Buy
1,780,638
+1,497,144
+528% +$24.6M 0.01% 1164
2020
Q1 		$3.33M Buy
283,494
+21,337
+8% +$401K ﹤0.01% 2112
2019
Q4 		$6.16M Sell
262,157
-26,518
-9% -$587K ﹤0.01% 2037
2019
Q3 		$5.34M Hold
288,675
– – ﹤0.01% 2095
2019
Q2 		$5.37M Buy
288,675
+4
+0% +$80 ﹤0.01% 2134
2019
Q1 		$7.05M Sell
288,671
-214
-0.1% -$5.6K ﹤0.01% 1771
2018
Q4 		$7.49M Sell
288,885
-1,209
-0.4% -$33.2K ﹤0.01% 1696
2018
Q3 		$9.18M Sell
290,094
-160,597
-36% -$5.98M ﹤0.01% 1762
2018
Q2 		$17.5M Sell
450,691
-2,427
-0.5% -$77.3K 0.01% 1319
2018
Q1 		$12.5M Sell
453,118
-122,147
-21% -$2.77M ﹤0.01% 1417
2017
Q4 		$10.4M Buy
575,265
+24
+0% +$391 ﹤0.01% 1550
2017
Q3 		$9.29M Sell
575,241
-71
-0% -$1.11K ﹤0.01% 1610
2017
Q2 		$7.97M Sell
575,312
-2,316,605
-80% -$33.6M ﹤0.01% 1683
2017
Q1 		$43.4M Buy
2,891,917
+2,306,098
+394% +$31.9M 0.01% 851
2016
Q4 		$7.67M Sell
585,819
-2,187,837
-79% -$34.3M ﹤0.01% 1712
2016
Q3 		$47.8M Sell
2,773,656
-135,935
-5% -$2.52M 0.02% 779
2016
Q2 		$52.5M Sell
2,909,591
-236,617
-8% -$4.62M 0.02% 735
2016
Q1 		$59.7M Sell
3,146,208
-166,177
-5% -$3.28M 0.02% 662
2015
Q4 		$88.4M Buy
3,312,385
+76,971
+2% +$2.06M 0.04% 554
2015
Q3 		$78.9M Buy
3,235,414
+2,268,459
+235% +$75.6M 0.03% 567
2015
Q2 		$30.1M Buy
+966,955
New +$18.2M 0.01% 1051

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Invesco's HRTX Position: Q1 2026 in Review

Invesco increased its Heron Therapeutics (HRTX) stake by 6.1% in Q1 2026, buying an estimated $21.6K and bringing the position to 326,512 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

Invesco first reported a position in HRTX in Q2 2015 and has held it in 44 quarters since. The position peaked at $88.4M in Q4 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Invesco held 326,512 shares of Heron Therapeutics worth $261K as of Q1 2026.
  • Invesco bought 18,651 Heron Therapeutics shares in Q1 2026, an estimated $21.6K.
  • Heron Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3395 holding.
  • Invesco first reported a position in Heron Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Invesco's Heron Therapeutics position peaked at $88.4M in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.